OP
PACB icon

ORG Partners’s Pacific Biosciences PACB Stock Holding History

ORG Partners’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1
Closed -$1 – 1650
2025
Q2 		$1 Buy
+1
New +$1 ﹤0.01% 1526
2025
Q1 		– Sell
-101
Closed -$184 – 1543
2024
Q4 		$184 Hold
101
– – ﹤0.01% 1231
2024
Q3 		$171 Hold
101
– – ﹤0.01% 1111
2024
Q2 		$121 Buy
+101
New +$204 ﹤0.01% 1742
2024
Q1 		– Sell
-1
Closed -$9 – 912
2023
Q4 		$9 Buy
+1
New +$8 ﹤0.01% 1113

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $7.59B AUM 23.44% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.39B AUM 10.34% 1-Year Est. Return

ORG Partners's PACB Position: Q3 2025 in Review

ORG Partners sold out of Pacific Biosciences (PACB) in Q3 2025, closing a stake of 1 share — an estimated $1 sold.

ORG Partners first reported a position in PACB in Q4 2023 and held it in 5 quarters. The position peaked at $184 in Q4 2024. 208 funds tracked by Wall St. Rank hold PACB as of Q3 2025.

  • ORG Partners reported no remaining Pacific Biosciences position as of Q3 2025 after selling out during the quarter.
  • ORG Partners sold 1 Pacific Biosciences share in Q3 2025, an estimated $1.
  • ORG Partners first reported a position in Pacific Biosciences in Q4 2023 and held it in 5 quarters.
  • ORG Partners's Pacific Biosciences position peaked at $184 in Q4 2024.
  • 208 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2025.

Based on ORG Partners's 13F filing for Q3 2025, filed 24 Oct 2025.